Cue Biopharma (NASDAQ:CUE) Stock Price Up 19.9% – Here’s What Happened

Cue Biopharma, Inc. (NASDAQ:CUE) shares rose 19.9% on Monday . The company traded as high as $30.75 and last traded at $30.43. 163,488 shares changed hands during trading, an increase of 112% from the average session volume of 76,983 shares. The stock had previously closed at $25.39.

Analyst Ratings Changes

A number of analysts have commented on CUE shares. Wall Street Zen upgraded shares of Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Cue Biopharma Price Performance

The company has a market capitalization of $127.81 million, a price-to-earnings ratio of -5.45 and a beta of 2.51. The stock has a 50-day moving average price of $71.85 and a 200-day moving average price of $213.26.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.30) by $2.22. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.The business had revenue of $5.69 million for the quarter, compared to analyst estimates of $2.50 million.

Hedge Funds Weigh In On Cue Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC acquired a new position in shares of Cue Biopharma in the third quarter valued at $439,000. Stifel Financial Corp lifted its stake in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma during the 3rd quarter worth about $62,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after buying an additional 73,000 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc grew its stake in Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares during the last quarter. 35.04% of the stock is owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.